GE HealthCare launches clinical trial for mangaciclanol MRI agent
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 23 2026
0mins
Source: Newsfilter
GE HealthCare Technologies Inc. has seen its stock price decline as it hits a 20-day low amid broader market weakness, with the Nasdaq-100 down 0.93% and the S&P 500 down 0.50%.
The company has initiated a Phase 2/3 clinical trial for its manganese-based MRI contrast agent, mangaciclanol, at Mayo Clinic, marking a significant step in its innovative imaging agents portfolio. This trial, along with the FDA's Fast Track designation for the agent, underscores GE HealthCare's commitment to advancing medical imaging technology and enhancing patient care. However, the stock's performance is currently overshadowed by the overall market downturn.
Despite the promising developments with mangaciclanol, the stock's decline reflects the challenging market environment, prompting investors to weigh the potential long-term benefits of the clinical trial against immediate market pressures.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GEHC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GEHC
Wall Street analysts forecast GEHC stock price to rise
13 Analyst Rating
8 Buy
5 Hold
0 Sell
Moderate Buy
Current: 62.860
Low
80.00
Averages
92.25
High
105.00
Current: 62.860
Low
80.00
Averages
92.25
High
105.00
About GEHC
GE HealthCare Technologies Inc. is a healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first artificial intelligence (AI)-enabled solutions, services and data analytics. Its business segments include Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its AVS segment offers ultrasound, image guided therapies, and interventional solutions with a portfolio that spans the continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. Its PCS segment consists of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment develops and produces two types of imaging agents: contrast media and radiopharmaceuticals.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
UBS Upgrades GE HealthCare to Neutral Amid Stock Decline
- Rating Upgrade: UBS upgraded GE HealthCare from Sell to Neutral and lowered its price target from $75 to $69, reflecting a reassessment of the company's stock valuation as shares trade near a 52-week low of $64.
- Stock Decline Reasons: GE HealthCare's stock fell approximately 30% following its Q1 earnings report, primarily due to disappointing results with $5.1 billion in quarterly revenue and an adjusted EPS of $0.99, missing the expected $1.05.
- Cost Pressures: Management highlighted that a supplier recall exacerbated margin pressures stemming from rising costs related to memory chips, oil prices, and freight, leaving little room to offset these headwinds in the short term.
- Long-Term Growth Confidence: Despite short-term challenges, GE HealthCare's leadership reaffirmed its long-term growth trajectory at the Bank of America Global Healthcare Conference, anticipating that cost initiatives, pricing actions, and new product launches will help restore margin improvement.
See More
MercadoLibre and GE Healthcare Executives Increase Stock Holdings
- Executive Purchases: MercadoLibre Director Alejandro Nicolas Aguzin disclosed in an SEC filing that he bought 600 shares of MELI at $1,655.93 each on Friday, totaling an investment of $993,556, marking his first purchase in the past twelve months, indicating confidence in the company's future.
- Market Reaction: Following the news of Aguzin's purchase, MercadoLibre's stock rose approximately 2.3% on Wednesday, reflecting a positive market response to insider buying, which may bolster investor confidence in the company's outlook.
- GE Healthcare Purchase: On the same day, GE HealthCare Technologies Director Kevin Lobo purchased $641,800 worth of stock, acquiring 10,000 shares at $64.18 each, demonstrating confidence in the company's growth potential.
- Profit Performance: As of Wednesday, Lobo's investment has yielded a gain of about 2.3%, based on the day's high trading price of $65.63, indicating market optimism for GE HealthCare, which could drive its stock price higher in the future.
See More
Investigation into GE HealthCare's Possible Securities Law Violations
- Poor Financial Performance: GE HealthCare reported adjusted earnings per share of $0.99 for Q1 2026 and lowered its full-year adjusted EPS guidance to a range of $4.80 to $5.00, down from $4.95 to $5.15, indicating a significant decline in profitability.
- Recall Impact: Management disclosed during the earnings call that profit performance was affected by a recall associated with a PDx supplier, and year-over-year margin performance was also impacted by declines in PCS and the PDx supplier issue, highlighting potential risks in supply chain management.
- Significant Stock Drop: Following the earnings report, GE HealthCare's stock price fell by $9.01, or 13.2%, closing at $59.49 per share, which may raise investor concerns regarding the company's future performance.
- Ongoing Legal Investigation: The Law Offices of Howard G. Smith are investigating on behalf of GE HealthCare investors regarding potential violations of federal securities laws, indicating that legal risks could impact the company's reputation and investor confidence.
See More
GE HealthCare Reports Q1 Earnings Miss, Shares Plunge
- Earnings Report Miss: In Q1 2026, GE HealthCare reported adjusted EPS of $0.99, falling short of the $1.05 consensus estimate, indicating potential profitability challenges that could undermine investor confidence.
- Guidance Downgrade: The company revised its full-year 2026 adjusted EPS guidance down to a range of $4.80 to $5.00 from the previous $4.95 to $5.15, reflecting a cautious outlook on future performance.
- Significant Stock Decline: Following the earnings announcement, GE HealthCare's stock price plummeted from $68.50 to $59.49, a drop of approximately 13%, suggesting heightened market concerns regarding the company's prospects and prompting investors to reassess their positions.
- Ongoing Legal Investigation: Kirby McInerney LLP is investigating potential violations of federal securities laws by GE HealthCare and its senior management; while no lawsuits have been filed yet, this inquiry could further impact the company's reputation and stock price.
See More
Latest Wall Street Ratings Overview
- SailPoint Coverage Initiation: Roth initiates coverage of SailPoint with a Buy rating and a price target of $19, highlighting its leadership in Identity Governance and Administration, which is expected to drive future growth potential.
- Brown & Brown Market Outperform: Citizens initiates coverage of Brown & Brown with a Market Outperform rating and a $70 price target, indicating significant upside potential driven by strong market demand and business outlook.
- Ameren Upgrade: JPMorgan upgrades Ameren from Neutral to Overweight, noting that the growing demand from data centers will enhance the company's earnings outlook, with a significant potential increase in EPS CAGR.
- FedEx Rating Reinstatement: Citi reinstates a Buy rating on FedEx with a target price of $443, citing the company's strong performance amid macroeconomic shifts, solid execution, and value unlock from recent spin-offs.
See More
GE HealthCare Faces Investor Lawsuit Investigation
- Earnings Miss: GE HealthCare reported adjusted earnings per share of $0.99 for Q1 2026, falling short of the $1.05 consensus estimate, which led to a downward revision of its full-year adjusted EPS guidance to a range of $4.80 to $5.00, indicating a significant decline in profitability.
- Stock Price Plunge: Following the disappointing earnings report, GE HealthCare's stock price dropped by $9.01, or approximately 13%, from $68.50 on April 28, 2026, to $59.49 on April 29, reflecting market concerns about the company's future performance.
- Legal Investigation Initiated: Bragar Eagel & Squire, P.C. is investigating whether GE HealthCare has violated federal securities laws or engaged in other unlawful business practices, highlighting concerns regarding corporate governance and compliance.
- Investor Rights Advocacy: The law firm is encouraging all investors who purchased GE HealthCare shares during this period and suffered losses to reach out, indicating potential risks and opportunities for compensation related to the company's legal liabilities.
See More
UBS Upgrades GE HealthCare to Neutral Amid Stock Decline
- Rating Upgrade: UBS upgraded GE HealthCare from Sell to Neutral and lowered its price target from $75 to $69, reflecting a reassessment of the company's stock valuation as shares trade near a 52-week low of $64.
- Stock Decline Reasons: GE HealthCare's stock fell approximately 30% following its Q1 earnings report, primarily due to disappointing results with $5.1 billion in quarterly revenue and an adjusted EPS of $0.99, missing the expected $1.05.
- Cost Pressures: Management highlighted that a supplier recall exacerbated margin pressures stemming from rising costs related to memory chips, oil prices, and freight, leaving little room to offset these headwinds in the short term.
- Long-Term Growth Confidence: Despite short-term challenges, GE HealthCare's leadership reaffirmed its long-term growth trajectory at the Bank of America Global Healthcare Conference, anticipating that cost initiatives, pricing actions, and new product launches will help restore margin improvement.
See More
MercadoLibre and GE Healthcare Executives Increase Stock Holdings
- Executive Purchases: MercadoLibre Director Alejandro Nicolas Aguzin disclosed in an SEC filing that he bought 600 shares of MELI at $1,655.93 each on Friday, totaling an investment of $993,556, marking his first purchase in the past twelve months, indicating confidence in the company's future.
- Market Reaction: Following the news of Aguzin's purchase, MercadoLibre's stock rose approximately 2.3% on Wednesday, reflecting a positive market response to insider buying, which may bolster investor confidence in the company's outlook.
- GE Healthcare Purchase: On the same day, GE HealthCare Technologies Director Kevin Lobo purchased $641,800 worth of stock, acquiring 10,000 shares at $64.18 each, demonstrating confidence in the company's growth potential.
- Profit Performance: As of Wednesday, Lobo's investment has yielded a gain of about 2.3%, based on the day's high trading price of $65.63, indicating market optimism for GE HealthCare, which could drive its stock price higher in the future.
See More
Investigation into GE HealthCare's Possible Securities Law Violations
- Poor Financial Performance: GE HealthCare reported adjusted earnings per share of $0.99 for Q1 2026 and lowered its full-year adjusted EPS guidance to a range of $4.80 to $5.00, down from $4.95 to $5.15, indicating a significant decline in profitability.
- Recall Impact: Management disclosed during the earnings call that profit performance was affected by a recall associated with a PDx supplier, and year-over-year margin performance was also impacted by declines in PCS and the PDx supplier issue, highlighting potential risks in supply chain management.
- Significant Stock Drop: Following the earnings report, GE HealthCare's stock price fell by $9.01, or 13.2%, closing at $59.49 per share, which may raise investor concerns regarding the company's future performance.
- Ongoing Legal Investigation: The Law Offices of Howard G. Smith are investigating on behalf of GE HealthCare investors regarding potential violations of federal securities laws, indicating that legal risks could impact the company's reputation and investor confidence.
See More
GE HealthCare Reports Q1 Earnings Miss, Shares Plunge
- Earnings Report Miss: In Q1 2026, GE HealthCare reported adjusted EPS of $0.99, falling short of the $1.05 consensus estimate, indicating potential profitability challenges that could undermine investor confidence.
- Guidance Downgrade: The company revised its full-year 2026 adjusted EPS guidance down to a range of $4.80 to $5.00 from the previous $4.95 to $5.15, reflecting a cautious outlook on future performance.
- Significant Stock Decline: Following the earnings announcement, GE HealthCare's stock price plummeted from $68.50 to $59.49, a drop of approximately 13%, suggesting heightened market concerns regarding the company's prospects and prompting investors to reassess their positions.
- Ongoing Legal Investigation: Kirby McInerney LLP is investigating potential violations of federal securities laws by GE HealthCare and its senior management; while no lawsuits have been filed yet, this inquiry could further impact the company's reputation and stock price.
See More
Latest Wall Street Ratings Overview
- SailPoint Coverage Initiation: Roth initiates coverage of SailPoint with a Buy rating and a price target of $19, highlighting its leadership in Identity Governance and Administration, which is expected to drive future growth potential.
- Brown & Brown Market Outperform: Citizens initiates coverage of Brown & Brown with a Market Outperform rating and a $70 price target, indicating significant upside potential driven by strong market demand and business outlook.
- Ameren Upgrade: JPMorgan upgrades Ameren from Neutral to Overweight, noting that the growing demand from data centers will enhance the company's earnings outlook, with a significant potential increase in EPS CAGR.
- FedEx Rating Reinstatement: Citi reinstates a Buy rating on FedEx with a target price of $443, citing the company's strong performance amid macroeconomic shifts, solid execution, and value unlock from recent spin-offs.
See More
GE HealthCare Faces Investor Lawsuit Investigation
- Earnings Miss: GE HealthCare reported adjusted earnings per share of $0.99 for Q1 2026, falling short of the $1.05 consensus estimate, which led to a downward revision of its full-year adjusted EPS guidance to a range of $4.80 to $5.00, indicating a significant decline in profitability.
- Stock Price Plunge: Following the disappointing earnings report, GE HealthCare's stock price dropped by $9.01, or approximately 13%, from $68.50 on April 28, 2026, to $59.49 on April 29, reflecting market concerns about the company's future performance.
- Legal Investigation Initiated: Bragar Eagel & Squire, P.C. is investigating whether GE HealthCare has violated federal securities laws or engaged in other unlawful business practices, highlighting concerns regarding corporate governance and compliance.
- Investor Rights Advocacy: The law firm is encouraging all investors who purchased GE HealthCare shares during this period and suffered losses to reach out, indicating potential risks and opportunities for compensation related to the company's legal liabilities.
See More
